A survey on adverse drug reaction studies: data, tasks and machine learning methods

Duc Anh Nguyen, Canh Hao Nguyen and Hiroshi Mamitsuka

Corresponding author: Tel.: +81-774-38-3023 Fax: +81-774-38-3037; E-mail: ducanh@kuicr.kyoto-u.ac.jp

Abstract

Motivation: Adverse drug reaction (ADR) or drug side effect studies play a crucial role in drug discovery. Recently, with the rapid increase of both clinical and non-clinical data, machine learning methods have emerged as prominent tools to support analyzing and predicting ADRs. Nonetheless, there are still remaining challenges in ADR studies. **Results:**In this paper, we summarized ADR data sources and review ADR studies in three tasks: drug-ADR benchmark data creation, drug–ADR prediction and ADR mechanism analysis. We focused on machine learning methods used in each task and then compare performances of the methods on the drug–ADR prediction task. Finally, we discussed open problems for further ADR studies. **Availability:** Data and code are available at https://github.com/anhnda/ADRPModels. **Supplementary:** Supplementary materials are available at *Briefings in Bioinformatics* online.

Key words: adverse drug reaction; ADR prediction; ADR mechanism; machine learning methods

Introduction

According to WHO, an adverse drug reaction (ADR) or drug side effect is a response to a medicine that is noxious and unintended, and which occurs at doses normally used in human [1]. In reports of 2011, ADRs accounted for nearly 6% of total hospitalizations in the USA, which cost billions of dollars and were responsible for significant patient morbidity and mortality [2, 3]. Therefore, the studies of ADRs are important in drug discovery.

The traditional methods for obtaining ADRs of drugs often use clinical trials or post-marketing surveillance reports [4]. However, these methods are costly and time-consuming. To deal with these disadvantages, machine learning methods integrating various kinds of ADR data sources are used to make inexpensive and fast predictions. These results provide potential ADRs and their mechanism analysis for further clinical verification to enhance ADR studies.

Data sources used in ADR studies consist of clinical and non-clinical data. The clinical data contains observations of ADRs from clinical treatments of patients. These observations have not only ADRs but also personal contexts, such as dosages of treatments, ages, genders and diseases of patients. Since different patients can have different ADRs, such personal contexts can support to build personalized ADR prediction models.

The non-clinical data contain information of biological systems such as drug–protein interactions and biological processes. In fact, there are various possible mechanisms in ADRs, for

Duc Anh Nguyen is currently a PhD student at the Bioinformatics Center in Kyoto University. His current research interests focus on machine learning and bioinformatics.
Canh Hao Nguyen is an assistant professor at the Bioinformatics Center, Institute for Chemical Research, Kyoto University, working on machine learning for graph data, with applications to biological networks.
Hiroshi Mamitsuka is a professor at the Bioinformatics Center, Institute for Chemical Research, Kyoto University, and a FiDiPro professor at the Department of Computer Science, Aalto University, working on machine learning, data mining and application to biology and chemistry.

TABLE 1. Recent surveys on ADR studies

	Task		Data		Method analysis
Paper	Clinical data extraction	Drug-ADR prediction	Clinical data	Drug-ADR and non-clinical data	
Poloju and Muniganti, 2018 [7]	✓		✓		
Chen *et al.*, 2016 [8]		✓		✓	✓
Ho *et al.*, 2016 [9]	✓	✓	✓	✓	

example, by interactions of drugs with proteins, but the details of these mechanisms are still unknown [5, 6]. By integrating clinical data with non-clinical data, it is expected that the quality of ADR studies will be improved, and ADR mechanisms can be revealed.

Since there are different machine learning methods using various kinds of ADR data sources, an overview of current methods in ADRs is necessary. Table 1 summarizes the most recent survey papers related to ADR studies. These studies often use either clinical data [7] or non-clinical data [8]. There is only one survey that uses both kinds of data [9], but there is no detailed analysis on methods, such as providing a taxonomy or conducting experiments to compare performances of methods. Recently, there are new studies in ADRs with the emerging of using machine learning methods, leading to a need for a more detailed classification for these methods. Moreover, ADR studies are not only drug-ADR prediction [8] but also analyzing ADR mechanisms by revealing biological components associated with ADRs [10]. Motivated by this, we give a broader view of ADR studies containing ADR data sources and how computational tasks of ADRs use these kinds of data.

The contributions of our paper can be summarized as follows. (i) We summarize the ADR data sources containing both clinical and non-clinical data. (ii) We summarize a wide range of drug descriptors used in ADR studies. (iii) We analyze methods used in ADR studies in three main tasks: (a) drug-ADR benchmark data creation, (b) drug-ADR prediction and (c) ADR mechanism analysis (We focus on papers on the main journals with the most numbers of papers on this topic such as Bioinformatics, BMC Informatics, Briefing in Bioinformatics and Nucleic Acid Research, then we follow cited papers. Papers are collected up to February 2019.). In each task, we analyze data and commonly used machine learning methods. (iv) We conduct an experiment to compare the drug-ADR prediction performances of eight commonly used methods.

The organization of the paper is as follows: Section 2 presents the data sources used in ADR studies. Section 3 details different kinds of drug descriptors that encode drug information. ADR studies with tasks and methods are detailed in Section 4. Finally, discussions on current ADR studies and open problems are presented in Section 5.

Data sources in ADR studies

In this section, we summarize commonly used data sources in ADR studies. Figure 1 illustrates a hierarchical classification of data sources in ADR studies containing two groups: clinical and non-clinical data.

Clinical data

Clinical data contain observations of ADRs in clinical treatments, which are often electronic health records or records

TABLE 2. Commonly used clinical data sources

Data sources	Personel context	Drug-ADR benchmark	
		Monopharmacy	Polypharmacy
FAERS [13]	✓		
OMOP-CDM [15]	✓		
SIDER [16]		✓	
Liu' dataset [17]		✓	
AEOLUS [18]		✓	
OFFSIDES [19]		✓	
TWOSIDES [19]			✓

from adverse report systems. Each record contains drugs and observed ADRs. In addition, personal contexts such as demographic and dosage information are also stored. There is evidence that ADRs are different from different patients [11]; therefore, these personal contexts are important to build personalized ADR prediction models [12].

Table 2 provides the commonly used clinical data sources. For personal contexts, it has FDA Adverse Event Reporting System (FAERS) [13] and Medical Outcomes Partnership Common Data Model (OMOP CDM) [14]. There are four main tables in FAERS: demographics, drug, therapy and reaction. The demographics table describes patient information containing patient identification, age, gender, weight, location and other related information. The amount and routes of drug administration with patient identifications come from the drug table, and the time of drug treatments is from the drug therapy table. The reaction table contains the drug adverse reactions with patient identifications.

OMOP CDM is a data model provided by Observational Health Data Sciences and Informatics [15], which is an international collaboration with the aim to create and apply data analytic solutions to a large number of observational health databases. There are four domains of OMOP CDM v5.0: standardized clinical data, standardized health system data, standardized health economics data and standardized derived elements. Standardized clinical data contain the core information with clinical events and demographic information of patients. With OMOP CDM, millions of health records from different resources are transformed into pre-defined tables of the four domains, supporting further analysis [32].

FAERS was used to extract drug-ADR benchmark datasets, which contain reliable drug–ADR associations [16, 19]. SIDER, a common ADR benchmark dataset for many ADR studies, was extracted from FAERS for ADRs caused by single drugs (monopharmacy) [16]. Liu' dataset [17] is a benchmark dataset extracted from SIDER into the binary format with additional drug information. AEOLUS is also a monopharmacy dataset extracted from FAERS, and has more drug–ADR associations than SIDER. Extracting from FAERS with a criteria of removing bias data,

TABLE 3. Commonly used non-clinical databases

Database	Elements					Having Interactions
	Chemical / drug	Protein / gene	Pathway	ADR term	Disease	
DrugBank [20]	✓	✓				✓
PubChem [21]	✓					
PDB [22]		✓				
BindingDB [23]	✓	✓				✓
HPRD [24]		✓				✓
CTD [25]	✓	✓			✓	✓
KEGG [26]	✓	✓	✓		✓	✓
SuperTarget [27]	✓	✓				✓
ADReCS [28]				✓		
DART [29]					✓	✓
TTD [30]	✓	✓	✓		✓	✓
Bio2RDF [31]	✓	✓	✓	✓	✓	✓

OFFSIDES for ADRs caused by single drugs and TWOSIDES for ADRs caused by combinations of two drugs (polypharmacy) were created [19]. However, SIDER, AEOLUS, OFFSIDES and TWOSIDES only contain two kinds of information: drugs and ADRs. As far as we know, there is no benchmark ADR data for academic research that contains personal contexts such as diseases and duration of drug treatments.

In recent years, data from social media such as Facebook and Twitter are another kind of data to analyze ADR. This social media data contain comments of patients during drug treatments. However, the tasks on this kind of data are mainly ADR identification using techniques of natural language processing [33–35], which are considered as data pre-processing steps, therefore, we do not cover them in this survey.

Non-clinical data

The non-clinical data contain information of chemical, physical and biological properties of drugs and biological systems, which can help reveal mechanisms of drugs and ADRs. In fact, ADRs are results of complex reactions of drugs with biological components. Some studies have shown that drug side effects can be the results of reactions of drug chemicals with proteins [5, 6, 36], which interrupts normal biological processes leading to abnormal reactions of human bodies. By using this kind of data, we can improve the performance of models and extract possibly associated biological components with ADRs.

Table 3 summarizes the commonly used non-clinical databases in ADR studies in two aspects: elements in each database and interactions among elements existed or not. For example, ADReCS [28] is a database for only ADR term definitions, and KEGG [26] contains information of proteins, drugs, biological pathways, diseases and interactions among them such as drugs with proteins targets. To link these databases, Bio2RDF [31] provides interconnections among elements of different databases.

Finally, the connection between clinical and non-clinical data can be illustrated by a network in Figure 2. The clinical data provide information of drug-ADR connections with personal contexts. The non-clinical data contain connections of drug–drug, drug–protein, protein–protein and protein–biological pathway. This network is used to support some computational tasks represented in Section 4.


FIG. 1. Data source hierarchy in ADR studies.

FIG. 2. A network for clinical and non-clinical data.

TABLE 4. Two groups of structural descriptors implemented in CDK [40]

Group	Name	Number of descriptors
Variable-size	Daylight family [41]	-
	E-State fragments [42]	79
	Klekota-Roth [43]	4860
Fixed-size	MACCS keys [44]	166
	PubChem descriptors [21]	881
	CDK substructures [40]	307

Drug descriptors

One possible way of encoding drugs is to use descriptors, which are physical, chemical and biological characteristics of a drug. Since the quality of these descriptors impacts ADR prediction performances, the understanding of drug descriptors is a basic need. Figure 3 presents a classification for drug descriptors. In general, drug descriptors can be categorized into two classes: physical or chemical descriptors (PC-descriptors) and biological descriptors (BIO-descriptors).

PC-descriptors

The PC-descriptors describe the structure of drug molecules and their physical and chemical properties [37–39]. Based on their dimensionalities and properties, this class of descriptors can be divided into three subgroups: structural descriptors, spatial descriptors and other miscellaneous descriptors.

The structural descriptors describe features of molecular structures such as atom counters, atom pairs, rings and other substructures. Table 4 presents two groups of structural descriptors (fingerprints) implemented in Chemistry Development Kit (CDK) [40]: variable-size and fixed-size groups. The former group generates substructures from a given set of molecules, in which the number of substructures can be changed depending on the provided molecule set [41]. In contrast, the latter group uses pre-defined substructures, for example, MACCS keys and PubChem descriptors. An illustration of PubChem descriptors is shown in Figure 4. The PubChem descriptors contain pre-defined 881 bits, which are divided into seven sections with corresponding bits. For instance, bit 308, which belongs to section 3 of simple atom pairs, indicates the existence of O-H connection.

The spatial descriptors describe spatial properties of drug molecules. In PubChem 3D database [45], 3D conformers descriptors of molecules are used. These descriptors are calculated by OMEGA [46], a tool published by OpenEye. Molecular interaction fields (MIFs) are another kind of spatial descriptors for drugs. MIFs describe spatial variation of the interaction energy between a molecular target and a chosen probe. Probes are small molecules representing common interactions such as hydrophobic, hydrogen bond donors and acceptors [47]. Some well-known MIFs are GRID [48], VolSurf [49], CoMFA [50] and MetaSite [51]. Figure 5 illustrates the idea of GRID descriptors. A molecule is put into a cube with grids. An empirical energy function will be used to calculate the interaction field of each cell at position (x, y, z) of the cube. The energy function is defined by

$$E_{xyz} = \sum E_{lj} + \sum E_{el} + \sum E_{hb}$$


FIG. 3. Different kinds of drug descriptors.

FIG. 4. Seven sections in PubChem descriptors.

FIG. 5. A molecule with 3D GRID.

TABLE 5. Main notations

Notation	Description
$i \in \{1, \ldots, d\}$	A drug index in a set of given d drugs
$j \in \{1, \ldots, s\}$	An ADR index in a set of given s ADRs
$\mathbf{x}_i \in \mathbb{R}^e$	A descriptor vector of size e of drug i
$\mathbf{X} = [\mathbf{x}_1 \ldots \mathbf{x}_d]^T \in \mathbb{R}^{d \times e}$	A descriptor matrix of given d drugs, T is the transpose operator.
$y_{i,j} \in \mathbb{R}$	An association score of drug i and ADR j
$\mathbf{y}_i = [y_{i,1} \ldots y_{i,s}]^T \in \mathbb{R}^s$	A vector for association scores of drug i with s ADRs
$\mathbf{Y} = [\mathbf{y}_1 \ldots \mathbf{y}_d]^T \in \mathbb{R}^{d \times s}$	A given drug–ADR association score matrix
$\mathbf{h}_i \in \mathbb{R}^m$	A vector of size m representing associated biological components of drug i
$\mathbf{H} = [\mathbf{h}_1, \ldots, \mathbf{h}_d]^T \in \mathbb{R}^{d \times m}$	A given drug-biological component matrix

where E_{lj}, E_{el} and E_{eb} are the Lennard–Jones function, the electronic function and the hydrogen bound function, respectively [48].

Other miscellaneous descriptors such as physicochemical properties of drugs also affect the action of drugs. Lipophilicity [52, 53] impacts solubility, absorption, distribution, membrane penetration and plasma protein binding of drugs. Hydrogen bond [54] is another physical property of electrostatic attraction, which takes two out of five Lipinski's rules [55]. Size/geometric features of drugs such as molecular weight and atom counters can also reflect drug properties.

BIO-descriptors

The BIO-descriptors describe biological properties of drugs, which can be classified into two subgroups: function-based descriptors and interaction-profile descriptors. The function-based descriptors describe purposes of drugs in therapy. ATC code [56], which is a classification system for drugs based on therapeutic properties, is a typical example of function-based descriptors.

The interaction-profile descriptors describe associated biological components of drugs containing protein targets and associated biological pathways of drugs [17, 57]. These interaction-profile descriptors are taken from the databases having drug interaction information in Table 3, such as DrugBank [20], BindingDB [23] and Bio2RDF [31].

ADR studies: tasks, data and methods

In this section, we summarize three main computational tasks in ADR studies: (i) drug-ADR benchmark data creation, (ii) drug–ADR prediction and (iii) ADR mechanism analysis. Figure 6 provides an overview of ADR studies of these three tasks. In each task, we analyze objectives, data and commonly used methods. Main notations used in the following subsections are described in Table 5.

TABLE 6. Contingency table for Fisher's exact test

		Number of records of drugs	
		Drug i	Other drugs
ADR j	Yes	n_1	n_3
	No	n_2	n_4

Task 1: drug-ADR benchmark data creation

ADR clinical data contain millions of records with redundant information, for example, some records contain similar information. Creating a drug-ADR benchmark dataset is a necessary task in ADR studies. It helps other studies in evaluating performances of new methods and comparing with existing methods.

In ADR studies, benchmark data are extracted from clinical records to retrieve reliable drug–ADR associations, which are pairs of drugs with corresponding ADRs. However, drug-ADR pairs have different levels of association significance in clinical records. Some pairs of drug-ADR rarely appear in the clinical records, leading to their low association significance. In addition, some records often contain a combination of more than one drug, making the verification of drug–ADR associations difficult.

To check the significance of drug–ADR associations, association rule mining or statistical significance tests can be applied [58]. We will briefly explain a typical significance test, Fisher's exact test [59]. Consider drug i and ADR j in a clinical database, the association information of drug i and ADR j is stored into a contingency table as in Table 6. In this table, n_1 denotes the number of records containing ADR j of drug i, while n_2 is that of the other drugs. The number of records that do not contain ADR j of drug i is n_3, and that of the other drugs is n_4. The Fisher's exact test evaluates the significance of the association of drug i and ADR j by a P-value:

$$p = \frac{(n_1 + n_2)! \, (n_3 + n_4)! \, (n_1 + n_3)! \, (n_2 + n_4)!}{n_1! \, n_2! \, n_3! \, n_4! \, (n_1 + n_2 + n_3 + n_4)!}$$

This technique was used on FAERS to extract SIDER, a monopharmacy ADR benchmark dataset used in a large number of ADR studies [16, 60]. The technique was also used to extract OFFSIDES for monopharmacy ADR, which are ADRs of drugs that do not appear in the drug's package insert, and TWOSIDES for polypharmacy ADRs of drug–drug interactions [19].

Task 2: drug–ADR prediction

Predicting ADRs of drugs, or drug–ADR association scores, is a main objective of ADR studies. Depending on the personal context information is used or not, studies in drug–ADR prediction can be divided into two classes: personalized drug–ADR prediction and general drug–ADR prediction. In the following subsections, we analyze machine learning methods according to each class.

Personalized drug–ADR prediction

The personalized drug–ADR prediction uses personal contexts taken from clinical data with information such as dosages of treatments, gender and age of each patient. Therefore, the prediction result will be different among patients even with the same drugs. For this prediction, we focus on methods using

FIG. 6. Computational tasks of ADR studies: data and commonly used methods.

Poisson models, which are commonly used models for personalized drug–ADR prediction.

i. Poisson models

The aim of using Poisson models is to predict the probabilities of the numbers of occurrences of ADRs during drug treatments. It is assumed that these numbers follow Poisson distributions with expectations depending on the taken drugs [12, 32]. For simplicity, considering a patient p in a drug treatment, the probabilities of numbers of occurrences of s ADRs $\Phi(\tilde{\mathbf{y}}|\tilde{\mathbf{x}}) \in \mathbb{R}^s$ are calculated by

$$\Phi(\tilde{\mathbf{y}}|\tilde{\mathbf{x}}) = [P(\tilde{y}_1|\phi_1(\tilde{\mathbf{x}})) \ldots P(\tilde{y}_j|\phi_j(\tilde{\mathbf{x}})) \ldots P(\tilde{y}_s|\phi_s(\tilde{\mathbf{x}}))]^{\mathrm{T}}$$

where $\tilde{\mathbf{x}} = [\tilde{x}_{p,1} \ldots \tilde{x}_{p,i} \ldots \tilde{x}_{p,d}]^{\mathrm{T}}$ is a vector indicating drugs taken by patient p during the treatment, $\tilde{\mathbf{y}} = [\tilde{y}_1 \ldots \tilde{y}_j \ldots \tilde{y}_s]^{\mathrm{T}}$ is a vector denoting the numbers of occurrences of s ADRs and $P(\tilde{y}_j|\phi_j(\tilde{\mathbf{x}})) = \phi_j(\tilde{\mathbf{x}})^{\tilde{y}_j} e^{-\phi_j(\tilde{\mathbf{x}})}/\tilde{y}_j!$ is the Poisson distribution for the number of occurrences of ADR j with expectation $\phi_j(\tilde{\mathbf{x}})$. A commonly used formulation of ϕ_j is

$$\phi_j(\tilde{\mathbf{x}}) = \exp\left(\theta_{p,j} + \sum_{i=1}^{d} \tilde{x}_{p,i}.w_{i,j}\right)$$

where $\theta_{p,j}$ is a parameter depending on the patient, leading to differences in ADR occurrences of different patients, and $w_{i,j}$ is a parameter used as a weight for the association of drug i and ADR j [32]. This formulation shows a multiplicative contribution of each drug to the expectation of the number of occurrences of each ADR.

However, the existing Poisson models have a limitation in terms of integrating other information such as weights, genders of patients and also non-clinical data.

ii. Other methods

There are other methods that were used to combine drugs with personal contexts into medical case vectors. A feature-based similarity method was proposed to learn weights for these medical case vectors with the idea was to distinguish cases having an ADR with cases not having the ADR [61]. These medical case vectors were also used as inputs for a classification problem [62].

General drug–ADR prediction

In contrast to personalized drug–ADR prediction, general drug–ADR prediction predicts drug–ADR association scores without using personal contexts. A common approach for this class is to combine knowledge of drugs from non-clinical data to enrich drug information and apply machine learning methods to build drug–ADR prediction models. As presented in Section 3, drug information is described by various types of drug descriptors. The drug–ADR prediction models receive the drug descriptors as the inputs and output all corresponding ADRs.

In this study, we consider general drug–ADR prediction as a multi-label classification problem such that each ADR is a label and each drug can have many labels [64, 65]. The prediction models calculate the association scores, which are real numbers, of each drug with all labels. The final labels of the drug are selected from these scores by a ranking method. In detail, a drug–ADR prediction model is formulated as a function $\mathbf{f} : \mathbb{R}^e \rightarrow \mathbb{R}^s$, where e is the number of descriptors and s is the number of ADRs. Given a drug with descriptor vector $\mathbf{x} \in \mathbf{R}^e$, the model predicts drug–ADR association scores with s ADRs: $\mathbf{f}(\mathbf{x}) \in \mathbb{R}^s$.

We further classify the models into two classes: (i) non-latent variable models and (ii) latent variable models. Latent variables are ones that are not directly observed or measured, and needed to infer from observed data. Figure 7 presents an example of latent variables from a study on finding patterns of psychoactive substances used in adolescents [63]. There are thirteen psychoactive substances from beer to hallucinogenics, which are

FIG. 7. An example of latent variables with 13 psychoactive substances [63].

observed variables. In addition, there are some correlated pairs of substance usages, for example, cocaine and amphetamines. The study suggested that these substances can be grouped into three groups: alcohol, cannabis and hard drug. The patterns of substance usage will be taken from these three groups, which are called latent variables.

A latent variable model is a model that contains latent variables obtained from observed ones. In application to drug–ADR prediction, latent variables of drugs can be interpreted as groups of drug descriptors that are highly correlated with each other. The representations of drugs in the space created by latent variables are called latent vectors.

In the following contents, we first describe the formulation for function $\mathbf{f}$ according to models of the two classes: non-latent variable models and latent variable models, which are based on the criteria that latent vectors of drugs are learned or not. Then we present an experiment to compare prediction performances of these models.

i. *Non-latent variable models*

In non-latent variable models, drug descriptors are used to predict drug–ADR associations without learning drug latent vectors. We present three typical methods: (i) k nearest neighbors (k-NN), (ii) kernel methods and (iii) mining networks of drug-ADR.

(i) k-NN

The idea of using k-NN is that drugs having similar descriptor vectors tend to have similar ADRs [17, 64, 66–68]. Suppose that there is a similarity measure $sim : \mathbb{R}^e \times \mathbb{R}^e \rightarrow \mathbb{R}$, for example, cosine similarity. To predict drug–ADR association scores $\mathbf{f}(\mathbf{x})$, first the top k most similar drugs to $\mathbf{x}$ are identified resulting in a set of indices of the similar drugs $T(\mathbf{x}, k)$. Then the drug–ADR association scores are calculated by

$$\mathbf{f}(\mathbf{x}) = [f_1(\mathbf{x}) \ldots f_j(\mathbf{x}) \ldots f_s(\mathbf{x})]^{\mathrm{T}},$$

where f_j is a weighted average function:

$$f_j(\mathbf{x}) = \sum_{i \in T(\mathbf{x},k)} w_i(\mathbf{x}) y_{i,j}, \quad j \in \{1 \ldots s\},$$

with weights w_i are obtained from drug similarities, for example:

$$w_i(\mathbf{x}) = \frac{sim(\mathbf{x}, \mathbf{x}_i)}{\sum_{i' \in T(\mathbf{x},k)} sim(\mathbf{x}, \mathbf{x}_{i'})}. \tag{1}$$

Some extensions of KNN were also applied, for example the linear neighborhood similarity method (LNSM) [64]. In LNSM, the similarity weights are calculated such that a drug descriptor vector is a linear combination of descriptor vectors of the neighbor drugs with corresponding similarity weights.

(ii) Kernel methods

The idea of using kernel methods, for example, support vector machines (SVMs), is to use classification functions calculated from kernel functions in the form of inner products of drug descriptor vectors [17, 57, 67, 69]. To predict drug–ADR association scores $\mathbf{f}(\mathbf{x}) = [f_1(\mathbf{x}) \ldots f_j(\mathbf{x}) \ldots f_s(\mathbf{x})]^{\mathrm{T}}$, the kernel methods use the following form for f_j:

$$f_j(\mathbf{x}) = g(\sum_{i=1}^{d} w_{i,j} y_{i,j} K(\mathbf{x}, \mathbf{x}_i)), \quad j \in \{1 \ldots s\}$$

where g is a function, for example, a sign function. $K : \mathbb{R}^e \times \mathbb{R}^e \rightarrow \mathbb{R}$ is a kernel function, for example, a radial basis function (rbf): $K(\mathbf{x}, \mathbf{x}_i) = \exp(-\frac{(\mathbf{x}-\mathbf{x}_i)^{\mathrm{T}}(\mathbf{x}-\mathbf{x}_i)}{2\delta^2})$ with a hyperparameter δ, and $w_{i,j}$ is a parameter used as a weight for the association of drug i and ADR j.

Different from k-NN, the kernel methods learn weights from a training process, which depends on both drugs and ADRs, while weights in k-NN are calculated only from drug similarities.

c. Mining networks of drug–ADR

Consider a drug–ADR network $G = (V, E)$, where V is a set of nodes of d drug and s ADRs: $V = \{v_1, \ldots, v_i, \ldots, v_d\} \cup \{v_1, \ldots, v_j, \ldots, v_s\}$, and E is a set of edges of drug nodes–ADR nodes for known ADRs of drugs and drug nodes–drug nodes for drug similarities. The idea of mining this network is that if a drug and an ADR in the network are well-connected, they possibly have a high association score [70–72]. This approach can be formulated in two steps:

1. Calculate partial connection scores $r(v_i, v_j) \in \mathbb{R}^l$ of each pair of drug node v_i and ADR node v_j using l different measures on G. A commonly used measure is Jaccard index [70, 72]. Let $N_i = \{v|(v, v_i) \in E\}$ be a set of neighbor nodes of drug node v_i, and $N_j = \{v|(v, v_j) \in E\}$ be that of ADR node v_j, the partial connection score calculated by Jaccard index is $|N_i \cap N_j|/|N_i \cup N_j|$, where $|\dot{i}|$ denotes the cardinality of a set. Some other measures such as Dice index and Adamic/Adar index were also applied [72]. Random walk [73] was also applied to calculate r [74].

2. Calculate drug–ADR association scores $\mathbf{f}(\mathbf{x})$ of a drug with descriptor vector $\mathbf{x}$. Let $v(\mathbf{x})$ be the corresponding node in G

of the drug. The association scores are obtained by

$$\mathbf{f}(\mathbf{x}) = [f(r(v(\mathbf{x}), v_1)) \ldots f(r(v(\mathbf{x}), v_j)) \ldots f(r(v(\mathbf{x}), v_s))]^{\mathrm{T}}$$

where f was often a binary function [71] or a logistic regression function (LR) [70]. In addition, random forest (RF) was also applied to f [72].

However, a problem with mining drug–ADR networks is sparsity that there are too few edges between drugs and ADRs, for example, in SIDER dataset, the edge density is 0.017. This makes the prediction less effective since there is only a small number of ADRs predicted for each drug.

ii. *Latent variable models*

In latent variable models, drug–ADR association scores are calculated by using drug latent vectors learned from drug descriptors. Figure 8 illustrates two stages of using latent models: learning latent vectors of drugs and then using these latent vectors for prediction. It is expected that latent vectors can remove redundant information from drug descriptors, for example, unnecessary descriptors. In addition, calculating with latent vectors of small size can reduce complexity of high-dimensional data. In this paper, we briefly describe three commonly used latent variable models (canonical correlation analysis (CCA), matrix factorization (MF) and neural networks), and some other miscellaneous models.

(i) Canonical correlation analysis

The aim of using CCA is to find weight vectors $\mathbf{a} \in \mathbb{R}^e$ and $\mathbf{b} \in \mathbb{R}^s$ such that the correlation of the projections of drug descriptor matrix $\mathbf{X}$ and drug–ADR association matrix $\mathbf{Y}$ is maximized [57]:

$$\underset{\mathbf{a}, \mathbf{b}}{\arg\max} \frac{(\mathbf{Xa})^{\mathrm{T}}(\mathbf{Yb})}{\sqrt{(\mathbf{Xa})^{\mathrm{T}}(\mathbf{Xa})}\sqrt{(\mathbf{Yb})^{\mathrm{T}}(\mathbf{Yb})}}.$$

The first pair of $(\mathbf{Xa}, \mathbf{Yb})$ is called the first pair of canonical variables (latent variables). The remaining pairs of canonical variables have an additional constraint that they are uncorrelated with existing pairs of canonical variables. c pairs of weight vectors $\mathbf{a}$ and $\mathbf{b}$ form two weight matrices: $\mathbf{A} \in \mathbb{R}^{e \times c}$ and $\mathbf{B} \in \mathbb{R}^{s \times c}$, respectively.

The latent vector of a drug with descriptor vector $\mathbf{x}$ is calculated by $\mathbf{z}(\mathbf{x}) = \mathbf{A}^{\mathrm{T}}\mathbf{x}$. Drug–ADR association scores $\mathbf{f}(\mathbf{x})$ are obtained by minimizing the distance of latent vectors:

$$\mathbf{f}(\mathbf{x}) = \underset{\mathbf{y} \in \mathbb{R}^s}{\arg\min} \left\| \mathbf{z}(\mathbf{x}) - \mathbf{B}^{\mathrm{T}}\mathbf{y} \right\|.$$

where $\|.\|$ is a norm, for example, Euclidean norm.

Sparse canonical correlation analysis (SCCA), a variant of CCA, was also applied to predict drug–ADR association scores [67]. In SCCA, L_1 regularization is applied to columns of $\mathbf{A}$ and $\mathbf{B}$, leading to their sparsity.

(ii) Matrix factorization

The idea of using MF is illustrated in Figure 9 [75]. It is assumed that drugs and ADRs share c unknown latent variables. Then the drug–ADR association matrix $\mathbf{Y}$ is decomposed into two matrices of latent vectors of drugs and ADRs in the space of latent variables: $\mathbf{U} \in \mathbb{R}^{d \times c}$ and $\mathbf{V} \in \mathbb{R}^{s \times c}$, such that $\mathbf{Y} \approx \mathbf{UV}^{\mathrm{T}}$. Supposing there is a drug similarity matrix $\mathbf{S}_d \in \mathbb{R}^{d \times d}$ calculated from drug descriptors matrix $\mathbf{X}$, and an ADR similarity matrix $\mathbf{S}_s \in \mathbb{R}^{s \times s}$ calculated from ADR definitions, the objective function is

$$\underset{\mathbf{U}, \mathbf{V}}{\arg\min} \left\| \mathbf{Y} - \mathbf{UV}^{\mathrm{T}} \right\| + \Re(\mathbf{U}, \mathbf{V}, \mathbf{S}_d, \mathbf{S}_s),$$

where the first part is the error from MF, and the second one is the regularization for $\mathbf{U}$ and $\mathbf{V}$ given $\mathbf{S}_d$ and $\mathbf{S}_s$, for example, Laplacian regularization.

To calculate drug–ADR association scores $\mathbf{f}(\mathbf{x})$, first k-NN is applied to calculate a new latent vector $\mathbf{z}(\mathbf{x})$ from the existing drug latent vectors:

$$\mathbf{z}(\mathbf{x}) = \sum_{i \in T(\mathbf{x}, k)} w_i(\mathbf{x})\mathbf{u}_i$$

where $\mathbf{u}_i \in \mathbb{R}^c$ is the latent vector of drug i such that $\mathbf{u}_i^{\mathrm{T}}$ corresponds to the ith row of $\mathbf{U}$, $T(\mathbf{x}, k)$ is the set of indices of the top k most similar drugs to $\mathbf{x}$, and $w_i(\mathbf{x})$ are similarity weights defined in Equation 1.

Then, the drug–ADR association scores are obtained by

$$\mathbf{f}(\mathbf{x}) = \mathbf{Vz}(\mathbf{x}).$$

Different from CCA, MF only focuses on $\mathbf{Y}$ to learn latent vectors and uses $\mathbf{X}$ as additional information, which can be omitted from the regularization part. Meanwhile, CCA requires both $\mathbf{X}$ and $\mathbf{Y}$ to obtain latent vectors.

(iii) Neural networks

Neural networks, which are machine learning models featured by the ability to learn non-linear relationships, were applied to predict drug–ADR association [76–78]. Figure 10 illustrates this technique in detail. The basic components of neural networks are neurons. Each neuron receives an input vector $\mathbf{x}' = [x_1' \ x_2' \ldots x_n']^{\mathrm{T}}$ and outputs a value y' by a function: $y' = f(\mathbf{w}^{\mathrm{T}}\mathbf{x}' + b)$, where b is a bias, $\mathbf{w} = [w_1 \ w_2 \ldots w_n]^{\mathrm{T}}$ is a weight vector and f is an activation function, for example, a sigmoid function, making non-linear combinations. A neural network module is composed of multiple layers of neurons that the output of each neuron of a layer is used as an input for neurons of other layers. The outputs of a neural module, for example, named *Encoder*, given an input vector $\mathbf{x}$ is denoted by *Encoder*($\mathbf{x}$).

To predict drug–ADR association scores $\mathbf{f}(\mathbf{x})$, there are two steps to process:

1. Obtain the latent vector: $\mathbf{z}(\mathbf{x}) = Encoder(\mathbf{x})$, where *Encoder* is a neural module receiving drug descriptor vector $\mathbf{x}$ as the input vector.
2. Predict drug–ADR association scores: $\mathbf{f}(\mathbf{x}) = Decoder(\mathbf{z}(\mathbf{x}))$, where *Decoder* is a neural module receiving drug latent vector $\mathbf{z}(\mathbf{x})$ as the input vector.

An advantage of using neural networks is the ability to approximate any continuous function. If there is no hidden layer, neural networks become logistic regression functions. The architecture of neural networks can be more complex when changing connections of neurons and number of layers, for example, a multi-layer feedforward neural network (MLN) [77], or a deep convolutional neural network (DCN) [78]. These complex neural networks aim to approximate mapping functions from inputs to outputs better. However, the number of parameters in a neural network are often much larger than that of other models. This problem leads to increasing computational complexity and the potential for overfitting of neural networks.

FIG. 8. Learning latent variables and using latent variables.

FIG. 9. An illustration of matrix factorization.

FIG. 10. An illustration of a neural network.

TABLE 7. Statistics of the used dataset.

Num drugs	Num ADRs	Num drug-ADRs	Avg.	Min	ADRs/drug Max
1,385	2,707	605,121	445	1	2,703

(iv) Other methods

There are some miscellaneous methods to obtain latent vectors of drugs to predict drug–ADR associations, for example, mapping drugs into an ADR space [79–81] and mapping drugs into a metabolic reaction space [82]. In mapping drugs into an ADR space, groups of highly correlated ADRs were extracted, then each drug was represented by a vector over these groups. In mapping drugs into a metabolic reaction space, flux variability analysis was applied to represent drug–protein/gene interaction profiles by a vector over metabolic reactions [83], then these vectors were used to predict ADRs.

Performance comparison in general drug–ADR prediction

We conducted experiments to compare the general drug–ADR prediction performances on monopharmacy cases of eight machine learning models. There were four non-latent variable models: LNSM [64, 68], SVMs [17, 69], RF [17, 72] and LR [17, 70], and four latent variable models: CCA [57, 67], MF [75], MLN [77] and DCN [78] (The convolutional network proposed in [76] addressed polypharmacy ADRs, so we do not compare.).

i. *Experimental setups*

We ran experiments with AEOLUS dataset [18], a monopharmacy dataset for drug–ADR prediction, which was also used in [65] (AEOLUS is the largest one among AEOLUS, SIDER and Liu's datasets.). We only selected drugs appearing in DrugBank and ADRs occurring in more than 50 drugs. The final statistical information of the dataset is provided in Table 7, containing the number of drugs, the numbers of ADRs, the numbers of drug–ADR associations and the average, minimum and maximum numbers of ADRs per each drug.

In the experiments, we used PCBio and Chem2D as two kinds of drug descriptors with information presented in Table 8. PCBio descriptors are the combinations of PubChem descriptors taken from PubChem and chemical, physical and biological descriptors taken from Bio2RDF. We extracted descriptors with information from DrugBank in Bio2RDF as in [68], and selected descriptors occurring in at least three drugs. 2DChem descriptors are drug chemical descriptors represented in the form of a matrix such that each row of the matrix corresponds to chemical features of an atom in a drug. To represent 2DChem descriptors, we extracted 53 chemical properties of each atom in the drug's molecule, hence each drug is represented in the form of a matrix that the number of rows equals to the number of atoms of the drug and the number of columns is 53 (see supplement materials). In our experiments, 2DChem descriptors are only used for DCN model [78], other models use PCBio descriptors.

Two commonly used metrics were selected to evaluate prediction performance: area under the ROC curve (AUC) and area under the precision-recall curve (AUPR) [57, 64, 67, 79].

We used 10-fold cross-validation for the experiment. The hyperparameters of each model were selected by grid searches to obtain the highest prediction performances. In detail, the number of neighbors for LNSM was 60, SVMs were run with an rbf kernel and the soft-margin hyperparameter was 1. RF was

TABLE 8. Statistics of the used drug descriptors

Name	Source	Size
PCBio	Pubchem+Bio2RDF	7593
2DChem	Pubchem	[N_ATOMS_OF_DRUG,53]

TABLE 9. Performance comparison of drug–ADR prediction models on Aeolus dataset and PCBio descriptors. Results for AUC and AUPR contain mean and standard error values in the format *value* $\times 10^{-2}$

	Models						
	Non-latent models						Latent models
	LNSM	SVMs	RF	LR	CCA	MF	MLN
AUC ($\times 10^{-2}$)	86.07 ± 0.56	89.26 ±0.47	86.82 ±0.41	89.00 ±0.40	64.51 ±1.05	87.13 ±0.03	**89.55 ±0.39**
AUPR ($\times 10^{-2}$)	59.04 ±1.58	67.57 ±1.63	61.92 ±1.11	66.75 ±1.08	34.17 ±2.07	61.03 ±1.13	**68.70 ±1.23**
Time (s)	73	22642	181	3658	317	**25**	186

TABLE 10. Summary of the models in terms of performance, non-linearity and dimensional reduction

	Models	AUC ranking	Time ranking	Non-linearity	Dimensional reduction
Non-latent	LNSM	6	2		
	SVMs	2	8	✓	
	RF	5	3	✓	
	LR	3	6	✓	
Latent	CCA	7	4		✓
	MF	4	1		✓
	MLN	1	4	✓	✓
	DCN	8	7	✓	✓

run with 80 estimators. CCA had 60 pairs of canonical variables, MF had 60 latent factors and MLF had two hidden layers with the sizes of 1000 and 800. DCN had the same architecture described in [78] with four convolutional and pooling layers. The detail of selecting hyperparamters is provided in the supplemental material.

We calculated the average computational time of each fold. The computational time was evaluated on a computer with Intel Core i7-6700 CPU and 16 GB RAM.

ii. *Experimental results*

The results of prediction performances and computational time are presented in Table 9. In addition, DCN with 2DChem descriptors achieved 73.80±0.46 in AUC, 39.10±0.63 in AUPR and 4862(s) of computational time.

The results show that MLN is the model having the highest prediction performances in both AUC and AUPR (89.55 $\times 10^{-2}$ and 68.70 $\times 10^{-2}$). SVMs are the second highest model with 89.26 $\times 10^{-2}$ and 67.57 $\times 10^{-2}$ for AUC and AUPR. In terms of computational time, MF is the fastest model, and SVMs are the slowest one. CCA and DCN are the two models having the lowest prediction performances.

We summarize the properties of the models in terms of linearity and dimensional reduction, and rank the performances of the models in AUC and computational time as in Table ??. This table shows that in balancing between prediction accuracy and computational time, two latent variable models, MLN and MF, are the two most promising ones. In addition, latent variable models learn latent representation vectors of small size for drugs, which are much smaller than the original size of the drug descriptor vectors. This dimensional reduction can help to remove redundant information from drug descriptors. We

also can see that three out of the four highest AUC models are non-linear, suggesting that there are non-linear relationships between drug descriptors and ADRs.

Task 3: ADR mechanism analysis

The objective of this task is to reveal associated biological components such as proteins or pathways of ADRs. In this task, non-clinical data of drug–protein interactions, protein-pathways and chemical-pathways are combined with clinical data, usually drug-ADR benchmark data. There are two commonly used approaches for this task: (i) using sparse learning and (ii) using network mining.

i. *Using sparse learning*

In the sparse learning approach, the idea is to consider associated biological components of each drug as a feature vector, and then find associated features corresponding to ADRs. To do this, weight vectors over biological components and ADR are used with sparse constraints by applying *L*1 regularization. Remaining subsets with high weights of biological components and ADRs are associated with each other. We describe two studies using this approach with logistic regression and CCA.

Logistic regression with regularization was proposed to obtain associated biological pathways with each ADR [84]. To obtain pathways associated with ADR j, let $\mathbf{w}_j \in \mathbb{R}^m$ be weights over m pathways obtaining from

$$\arg\min_{\mathbf{w}_j} \frac{1}{d} \sum_{i=1}^{d} \left(-y_{i,j} \log \frac{1}{1 + \exp(-\mathbf{h}_i \cdot \mathbf{w}_j)} \right.$$

$$\left. - (1 - y_{i,j}) \log(1 - \frac{1}{1 + \exp(-\mathbf{h}_i \cdot \mathbf{w}_j)}) \right) + \lambda_w \|\mathbf{w}_j\|_1$$

where λ_w is a regularization parameter.

$L1$ regularization $\|\mathbf{w}_j\|_1$ forces $\mathbf{w}_j$ to be a sparse vector. The corresponding pathways with high weights are associated with ADR j.

SCCA was applied to obtain subsets of correlation of ADRs and pathways [85]. By applying SCCA into two matrices $\mathbf{Y}$ and $\mathbf{H}$ of drug-ADR and drug-biological component, respectively, two sparse weight matrices $\mathbf{A} \in \mathbb{R}^{s \times c}$ and $\mathbf{B} \in \mathbb{R}^{m \times c}$ are obtained. The corresponding subsets of ADRs and pathways of each pair of $(\mathbf{a}_l, \mathbf{b}_l)$ with $l = 1 \ldots c$ are correlated.

ii. Using network mining

The idea of using networks of ADR-biological components is similar to mining drug–ADR networks for drug–ADR prediction. If a biological component and an ADR are well-connected in a network of biological component-ADR, they are highly associated with each other. The technique was used in [10, 86, 87] to build a protein–ADR network and discover associated proteins with each ADR. Dijkstra algorithm, a well-known method to calculate the shortest paths in a graph, was used on the network of biological components-ADR to obtain associated biological pathways of ADRs [88].

Discussion

This survey addresses ADR-related studies in three aspects: data, drug descriptors and tasks with corresponding methods. We divide data sources into clinical and non-clinical data. Clinical data contain important personal context information such as ADRs, diseases, dosages of treatments and demographic information. Non-clinical data contain more detailed information of drugs and biological systems with chemical, physical properties of drugs, drug–protein interactions and biological pathways.

We summarize the commonly used drug descriptors in ADR studies. In addition to traditional physical and chemical descriptors, many studies integrate biological descriptors of drugs to have better drug information.

There are three main tasks in ADR studies: creating drug-ADR benchmark data, drug–ADR prediction and ADR mechanism analysis. Association rule mining is the commonly used method for creating drug–ADR benchmark data. The drug–ADR prediction task is classified into two classes: personalized drug–ADR prediction and general drug–ADR prediction. In the former class, Poisson models are widely used. In the latter class, the commonly used machine learning models can be categorized into non-latent variable models and latent variable models. The non-latent variable models predict drug-ADR without learning latent variables, while the latent variable models learn latent vectors of small size to represent drugs such that these latent vectors can help the prediction efficiently. The experimental results show that MLN is the model having the highest prediction performances, and the latent variable models have the potential for further development. In ADR mechanism analysis, using sparse learning and network mining are two commonly used approaches.

From this survey, we have three remarks on problems in current ADR studies as follows in current ADR studies as follows:

1) Most of drug–ADR prediction studies address monopharmacy cases in SIDER benchmark data. There are few studies proposed models for polypharmacy prediction, for example, predicting with TWOSIDES benchmark data [76], in spite of the fact that most of significant ADRs come from drug combinations [19, 76].

2) ADR data sources are not effectively used. Recent ADR studies only use either clinical data without non-clinical data

information or use ADR benchmark data and non-clinical data without personal context information. There are no studies that combine full clinical data with non-clinical data. In addition, current ADR benchmark data such as SIDER, OFFSIDES and TWOSIDES only contain drugs and ADRs, other personal context information still remains in original clinical records.

3) Machine learning models are mostly used as black boxes for drug–ADR prediction, since they only output association scores of drugs and ADRs. In ADR discovery, explaining ADR mechanisms is a big challenge. It is not only a problem of predicting corresponding ADRs of drugs but also how ADRs occur. However, predicting and revealing ADR mechanisms are now considered as two separate parts. Designing drug–ADR prediction models that reveal related information of ADR mechanisms seems to be an important topic.

In conclusion, the use of machine learning models in ADR studies is likely to develop in the future. Effectively using available data with suitable models still remains a big challenge. It is not only drug–ADR prediction is an important task, but also revealing ADR mechanisms is another task to concentrate on.

Key Points

- Machine learning methods are prominent tools for ADR studies.
- There are three main tasks in ADR studies: creating ADR benchmark data, drug–ADR prediction and ADR mechanism analysis.
- For drug–ADR prediction, latent variables models have the potential for further development.
- Remaining issues of ADR studies: (i) There are very few drug–ADR prediction models addressing polypharmacy ADR, (ii) ADR data sources are not effectively used and (iii) drug–ADR prediction models lack the ability to explain ADR mechanisms.

Funding

References

1. World Health Organization: WHO (1972). Definitions. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/definitions.pdf (10 Sep 2019, date last accessed).

2. Poudel DR, Acharya P, Ghimire S, et al. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. *Pharmacoepidemiol Drug Saf* 2017; **26**(6): 635–41.

3. Weiss A, Elixhauser A, Bae J, et al. Origin of adverse drug events in US hospitals, 2011. *HCUP Statistical Brief* 2013;158.

4. Hoots, B. E., Xu, L., Kariisa, M., et al. (2018). *2018 annual surveillance report of drug-related risks and outcomes–united states*. CDC National Center for Injury Prevention and Control.

5. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. *Drug Saf* 1994; **11**(3): 196–212.

6. Mann RD, Andrews EB. *Pharmacovigilance*. New Jersey, United States: John Wiley & Sons, 2007.

7. Poloju N, Muniganti P. Adverse drug reaction detection using data mining approaches: a survey. *Int J R Trends Eng Res* 2018; **2018**.

8. Chen YG, Wang YY, Zhao XM. A survey on computational approaches to predicting adverse drug reactions. *Curr Top Med Chem* 2016; **16**(30): 3629–35.

9. Ho TB, Le L, Thai DT, et al. Data-driven approach to detect and predict adverse drug reactions. *Curr Pharm Des* 2016; **22**(23): 3498–526.

10. Wang X, Thijssen B, Yu H. Target essentiality and centrality characterize drug side effects. *PLoS Comput Biol* 2013; **9**(7):e1003119.

11. Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy. In: *Pharmacogenomics in Drug Discovery and Development*. Berlin, Germany: Springer, 2014, 301–22.

12. Bao Y, Kuang Z, Peissig P, et al. Hawkes process modeling of adverse drug reactions with longitudinal observational data. In *Machine Learning for Healthcare Conference*, 2017; **2017**:177–90. Proceedings of Machine Learning Research.

13. U.S. Food and Drug Administration (2019). Questions and answers on FDA's adverse event reporting system (FAERS). https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers (10 Sep 2019, date last accessed).

14. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. *Ann Intern Med* 2010; **153**(9): 600–6.

15. Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. *Stud Health Technol Inf* 2015; **216**:574.

16. Kuhn M, Letunic I, Jensen LJ, et al. The sider database of drugs and side effects. *Nucleic Acids Res* 2015; **44**(D1): D1075–9.

17. Liu M, Wu Y, Chen Y, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. *J Am Med Inf Assoc* 2012; **19**(e1): e28–35.

18. Banda JM, Evans L, Vanguri RS, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. *Sci Data* 2016; **3**(160026).

19. Tatonetti NP, Patrick PY, Daneshjou R, et al. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; **4**(125): 125ra31–1.

20. Wishart DS, Knox C, Guo AC, et al. Drugbank: a knowledgebase for drugs, drug actions and drug targets. *Nucleic Acids Res* 2007; **36**(Suppl_1): D901–6.

21. Kim S, Thiessen PA, Bolton EE, et al. Pubchem substance and compound databases. *Nucleic Acids Res* 2015; **44**(D1): D1202–13.

22. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. *Nucleic Acids Res* 2000; **28**(1): 235–42.

23. Liu T, Lin Y, Wen X, et al. Bindingdb: a web-accessible database of experimentally determined protein–ligand binding affinities. *Nucleic Acids Res* 2006; **35**(Suppl_1): D198–201.

24. Keshava Prasad T, Goel R, Kandasamy K, et al. Human protein reference database—2009 update. *Nucleic Acids Res* 2008; **37**(Suppl_1): D767–72.

25. Davis AP, Murphy CG, Saraceni-Richards CA, et al. Comparative toxicogenomics database: a knowledgebase and discovery tool for chemical–gene–disease networks. *Nucleic Acids Res* 2008; **37**(Suppl_1): D786–92.

26. Kanehisa M, Goto S. Kegg: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000; **28**(1): 27–30.

27. Günther S, Kuhn M, Dunkel M, et al. Supertarget and matador: resources for exploring drug–target relationships. *Nucleic Acids Res* 2007; **36**(Suppl_1): D919–22.

28. Cai M-C, Xu Q, Pan Y-J, et al. Adrecs: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms. *Nucleic Acids Res* 2014; **43**(D1): D907–13.

29. Ji ZL, Han LY, Yap CW, et al. Drug adverse reaction target database (DART). *Drug Saf* 2003; **26**(10): 685–90.

30. Chen X, Ji ZL, Chen YZ. Ttd: therapeutic target database. *Nucleic Acids Res* 2002; **30**(1): 412–5.

31. Belleau F, Nolin M-A, Tourigny N, et al. Bio2rdf: towards a mashup to build bioinformatics knowledge systems. *J Biomed Inf* 2008; **41**(5): 706–16.

32. Simpson SE, Madigan D, Zorych I, et al. Multiple self-controlled case series for large-scale longitudinal observational databases. *Biometrics* 2013; **69**(4): 893–902.

33. Huynh T, He Y, Willis A, et al. *Adverse drug reaction classification with deep neural networks*. In *Proceedings of COLING*. Coling, COLING2016.

34. Lee K, Qadir A, Hasan SA, et al. Adverse drug event detection in tweets with semi-supervised convolutional neural networks. In: *Proceedings of the 26th International Conference on World Wide Web*. WWW: International World Wide Web Conferences Steering Committee, 2017, 705–14.

35. Emadzadeh E, Sarker A, Nikfarjam A, et al. AMIA Annual Symposium Proceedings. In: *Hybrid Semantic Analysis for Mapping Adverse Drug Reaction Mentions in Tweets to Medical Terminology*. PubMed Central: American Medical Informatics Association, 2017, 2017, 679.

36. Ring J, Brockow K. Adverse drug reactions: mechanisms and assessment. *Eur Surg Res* 2002; **34**(1–2): 170–5.

37. Testa B, Kier LB. The concept of molecular structure in structure–activity relationship studies and drug design. *Med Res Rev* 1991; **11**(1): 35–48.

38. Todeschini R, Consonni V. *Handbook of Molecular Descriptors, Vol. 11*. New Jersey, United States: John Wiley & Sons, 2008.

39. Grisoni, F., Ballabio, D., Todeschini, R., et al. (2018). Molecular descriptors for structure–activity applications: a hands-on approach. In: *Computati onal Toxicology*, 3–53. Springer.

40. Steinbeck C, Han Y, Kuhn S, et al. The chemistry development kit (CDK): an open-source java library for chemo-and bioinformatics. *J Chem Inf Comput Sci* 2003; **43**(2): 493–500.

41. Daylight Chemica Information System, Inc (2018). Daylight Theory: Fingerprint. http://www.daylight.com/dayhtml/doc/theory/theory.finger.html (10 Sep 2019, date last accessed).

42. Hall LH, Kier LB. Electrotopological state indices for atom types: a novel combination of electronic, topological, and valence state information. *J Chem Inf Comput Sci* 1995; **35**(6): 1039–45.

43. Klekota J, Roth FP. Chemical substructures that enrich for biological activity. *Bioinformatics* 2008; **24**(21): 2518–25.

44. Durant JL, Leland BA, Henry DR, et al. Reoptimization of MDL keys for use in drug discovery. *J Chem Inf Comput Sci* 2002; **42**(6): 1273–80.

45. Bolton EE, Kim S, Bryant SH. Pubchem3d: conformer generation. *J Cheminform* 2011; **3**(1): 4.

46. Openeye scientific software (2018). OMEGA. https://www.eyesopen.com/omega (10 Nov 2018, date last accessed).

47. Wermuth CG. *The Practice of Medicinal Chemistry*. Massachusetts, United States: Academic Press, 2011.

48. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. *J Med Chem* 1985; **28**(7): 849–57.

49. Crivori P, Cruciani G, Carrupt PA, et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. *J Med Chem* 2000; **43**(11): 2204–16.

50. Kubinyi H. Comparative molecular field analysis (COMFA). *Encyclopedia Comput Chem* 1998; **1**:448–60.

51. Cruciani G, Carosati E, De Boeck B, et al. Metasite: understanding metabolism in human cytochromes from the perspective of the chemist. *J Med Chem* 2005; **48**(22): 6970–9.

52. Young RC, Mitchell RC, Brown TH, et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting h2 receptor histamine antagonists. *J Med Chem* 1988; **31**(3): 656–71.

53. Testa B, Caron G, Crivori P, et al. Lipophilicity and related molecular properties as determinants of pharmacokinetic behaviour. *CHIMIA Int J Chem* 2000; **54**(11): 672–7.

54. van de Waterbeemd, H. and Kansy, M. (1992). Hydrogen-bonding capacity and brain penetration. *CHIMIA Int J Chem*, **46**(7–8), 299–303.

55. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Delivery Rev* 1997; **23**(1–3): 3–25.

56. WHO Collaborating Centre for Drug Statistics Methodology (2019). Guidelines for ATC classification and DDD assignment. https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf, (10 Sep 2019, date last accessed).

57. Yamanishi Y, Pauwels E, Kotera M. Drug side-effect prediction based on the integration of chemical and biological spaces. *J Chem Inf Model* 2012; **52**(12): 3284–92.

58. Montastruc J-L, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. *Brit J Clin Pharmacol* 2011; **72**(6): 905–8.

59. Agresti A. A survey of exact inference for contingency tables. *Stat Sci* 1992; **7**(1): 131–53.

60. Kuhn M, Campillos M, Letunic I, et al. A side effect resource to capture phenotypic effects of drugs. *Mol Syst Biol* 2010; **6**(1): 343.

61. Yang F, Yu X, Karypis G. Signaling adverse drug reactions with novel feature-based similarity model. In: *Bioinformatics and Biomedicine (BIBM), 2014 IEEE International Conference on*. IEEE: IEEE, 2014, 593–6.

62. Chen AW. Predicting adverse drug reaction outcomes with machine learning. *Int J Community Med Public Health* 2018; **5**(3): 901–4.

63. Huba G, Wingard JA, Bentler PM. A comparison of two latent variable causal models for adolescent drug use. *J Pers Soc Psychol* 1981; **40**(1): 180.

64. Zhang W, Liu F, Luo L, et al. Predicting drug side effects by multi-label learning and ensemble learning. *BMC Bioinform* 2015; **16**(1): 365.

65. Muñoz E, Nováček V, Vandenbussche P-Y. Facilitating prediction of adverse drug reactions by using knowledge graphs and multi-label learning models. *Brief Bioinform* 2017; **20**(1): 190–202.

66. Cao D, Xiao N, Li Y, et al. Integrating multiple evidence sources to predict adverse drug reactions based on a systems pharmacology model. *CPT Pharmacometrics Syst Pharmacol* 2015; **4**(9): 498–506.

67. Pauwels E, Stoven V, Yamanishi Y. Predicting drug side-effect profiles: a chemical fragment-based approach. *BMC Bioinform* 2011; **12**(1): 169.

68. Muñoz E, Nováček V, Vandenbussche P-Y. Using drug similarities for discovery of possible adverse reactions. In: *AMIA Annual Symposium Proceedings* 2016, 2016;924. American Medical Informatics Association.

69. Jahid MJ, Ruan J. An ensemble approach for drug side effect prediction. In: *Bioinformatics and Biomedicine (BIBM), 2013 IEEE International Conference on*, Vol. **2013**. IEEE: IEEE, 2013, 440–5.

70. Cami A, Arnold A, Manzi S, et al. Predicting adverse drug events using pharmacological network models. *Sci Transl Med* 2011, 114; **3**:114ra127–7.

71. Lin J, Kuang Q, Li Y, et al. Prediction of adverse drug reactions by a network based external link prediction method. *Anal Methods* 2013; **5**(21): 6120–7.

72. Davazdahemami B, Delen D. A chronological pharmacovigilance network analytics approach for predicting adverse drug events. *J Am Med Inform Assoc* 2018; **25**(10): 1311–21.

73. Tong H, Faloutsos C, Pan J-Y. Fast random walk with restart and its applications. In: *Sixth International Conference on Data Mining (ICDM'06)*. IEEE: IEEE, 2006, 613–22.

74. Rahmani H, Weiss G, Méndez-Lucio O, et al. Arwar: a network approach for predicting adverse drug reactions. *Comput Biol Med* 2016; **68**:101–8.

75. Poleksic A, Xie L. Predicting serious rare adverse reactions of novel chemicals. *Bioinformatics* 2018; **1**:8.

76. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. *Bioinformatics* 2018; **34**(13): i457–66.

77. Wang C-S, Lin P-J, Cheng C-L, et al. Detecting potential adverse drug reactions using a deep neural network model. *J Med Internet Res* 2019; **21**(2):e11016.

78. Dey S, Luo H, Fokoue A, et al. Predicting adverse drug reactions through interpretable deep learning framework. *BMC Bioinform* 2018; **19**(21): 476.

79. Dimitri GM, Lió P. Drugclust: a machine learning approach for drugs side effects prediction. *Comput Biol Chem* 2017; **68**:204–10.

80. Xiao C, Zhang P, Chaowalitwongse WA, et al. *Adverse drug reaction prediction with symbolic latent dirichlet allocation*. In: Proceedings of the Thirty-First AAAI Conference on Artificial Intelligence: AAAI Press, 2017.

81. Lorberbaum T, Sampson KJ, Woosley RL, et al. An integrative data science pipeline to identify novel drug interactions that prolong the QT interval. *Drug Saf* 2016; **39**(5): 433–41.

82. Shaked I, Oberhardt MA, Atias N, et al. Metabolic network prediction of drug side effects. *Cell Syst* 2016; **2**(3): 209–13.

83. Mahadevan R, Schilling C. The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. *Metab Eng* 2003; **5**(4): 264–76.

84. Wallach I, Jaitly N, Lilien R. A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. *PLoS One* 2010; **5**(8): e12063.

85. Zheng H, Wang H, Xu H, et al. Linking biochemical pathways and networks to adverse drug reactions. *IEEE Trans Nanobiosci* 2014; **13**(2): 131–7.

86. Chen X, Liu X, Jia X, et al. Network characteristic analysis of ADR-related proteins and identification of ADR-ADR associations. *Sci Rep* 2013; **3**:1744.

87. Jiang Y, Li Y, Kuang Q, et al. Predicting putative adverse drug reaction related proteins based on network topological properties. *Anal. Methods* 2014; **6**(8): 2692–8.

88. Wang J, Li Z-x, Qiu C-x, et al. The relationship between rational drug design and drug side effects. *Brief Bioinform* 2011; **13**(3): 377–82.